MAPK3 and breast cancer: These findings warrant further investigation of the activity level of the ERK1/2 signaling pathway in patient samples to determine the frequency of ERK1/2 activation in early-stage breast cancer and whether there is a correlation between ERK1/2 activation and recurrent growth after lumpectomy.